Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis
About OPTIMA
Welcome to OPTIMA, a patient driven clinical study for people with hormone sensitive early breast cancer.
OPTIMA aims to improve the way we make decisions about whom we offer chemotherapy to following surgery.
**The first results of the OPTIMA trial were presented at ASCO 2026.
Please click here to see a copy of the presentation presented by Prof. Rob Stein, OPTIMA CI.
© 2019 OPTIMA.
The OPTIMA Study is funded by National Institute for Health Research (NIHR), Programme (project reference 10/34/501). The information contained in this website is for general information about the OPTIMA study and is provided by the University of Warwick Clinical Trials Unit & University College London. The views expressed are those of the author(s) and are not necessarily those of NIHR or the Department of Health and Social Care or representative of the views of the funder, sponsor or other participating organisations. Trial Registration Number ISRCTN42400492